Elevated plasma homocysteine levels in patients treated with levodopa: Association with vascular disease

Archives of Neurology

Volumn 60, Issue 1, 2003, Pages 59-64

  Rogers, John D ^a   Sanchez Saffon, Anna ^a   Frol, Alan B ^a   Diaz Arrastia, Ramon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; COBALAMIN; CYANOCOBALAMIN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHYLMALONIC ACID; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CYANOCOBALAMIN DEFICIENCY; DEMENTIA; DEPRESSION; DRUG METABOLISM; DRUG UTILIZATION; FEMALE; FOLIC ACID DEFICIENCY; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; METHYLATION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

EID: 0037225458     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.1.59     Document Type: Article

References (44)

1. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
2. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 1995;92:2825-2830.
3. 6, pyridoxal phosphate, and folate. Am J Cardiol. 1995;75:1107-1111.
4. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.
5. Eikelboom JW, Lonn E, Genest J, Hankey GJ, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363-375.
6. Bostom AG, Rosenber IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999;131:352-355.
7. Bell IR, Edman JS, Selhub J, et al. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand. 1992;86:386-390.
8. 12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol. 1998;55:1449-1455.
9. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriat Psychiatry. 1998;13:235-239.
10. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999;10:12-20.
11. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
12. Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA. 1983;249:2917-2921.
13. 6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996;63:306-314.
14. Bottiglieri T, Godfrey P, Flynn T, Carney MWP, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096-1098.
15. 12, and neuropsychiatric disorders. Nutr Rev. 1996;54:382-390.
16. Allain P, LeBouil A, Coredilet E, LeQuay L, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology. 1995;16:527-530.
17. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol. 1998;40:225-227.
18. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet. 1999;354:126-127.
19. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 2000;55:437-440.
20. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
21. Rasmussen K, Moller J. Methodologies of testing. In: Carmel R, Jacobsen DW, eds. Homocysteine in Health and Disease. New York, NY: Cambridge University Press; 2001:199-211.
22. Hankey GJ, Eikelenboom P. Homocysteine and vascular disease. Lancet. 1999;354:407-413.
23. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-1600.
24. 6 on clinical outcome after percutaneous coronary intervention. JAMA. 2002;288:973-979.
25. Jacques PF, Rosenberg IH, Rogers G, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the Third National Health and Nutrition Examination Survey. Am J Clin Nutr. 1999;69:482-489.
26. Nygard O, Vollset SE, Refsum H, et al. Plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;274:1526-1533.
27. Stolzenberg-Solomon RZ, Miller ER, Maguire MG, Selhub J, Appel LJ. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am J Clin Nutr. 1999;69:467-475.
28. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114:473-501.
29. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York, NY: Marcel Dekker Inc; 1992:183-236.
30. Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia. 1999;40:345-350.
31. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk-factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
32. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410-2416.
33. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:569-573.
34. Morita H, Kurihara H, Sugiyama T, et al. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol. 1999;19:298-302.
35. Christensen B, Arbour L, Tran P, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Hum Genet. 1999;84:151-157.
36. Tsai MY, Welge BG, Hanson NQ, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery disease. Atherosclerosis. 1999;143:163-170.
37. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol. 2000;57:1422-1428.
38. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-dopa and the catechol-O-methyltransferase inhibitor Ro41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol. 1997;20:55-66.
39. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood. 1997;90:1-11.
40. Selhub J, D'Angelo G. Hyperhomocysteinemia and thrombosis: acquired conditions. Thromb Haemost. 1997;78:527-531.
41. Fabbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. Lancet. 1999;353:1586-1587.
42. Evers S, Koch H-G, Grotemeyer K-H, Lange B, Deufel T, Ringelstein E-B. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol. 1997;54:1276-1282.
43. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol. 1992;49:492-497.
44. Mayeux R, Williams JB, Stern Y, Cote L. Depression in Parkinson's disease. Adv Neurol. 1984;40:241-250.